Beyond Your CancerIsoray passionately designs and develops innovative and personalized brachytherapy products that effectively treat many forms of cancer. We believe in pioneering solutions for life beyond your cancer.
The introduction of Cesium-131 represents the culmination of decades of work and millions of dollars of investment. Top medical centers, hospitals and clinics across the United States are now offering this breakthrough treatment for cancer patients.
The word brachytherapy derives from the Greek prefix brachy, meaning “short” or “close,” because the titanium capsules containing the radioisotope are implanted directly into the cancerous prostate gland.
Treatment of cancer using low dose radiation or “seed” brachytherapy was pioneered in the 1960’s as an effective alternative to radical prostatectomy. Pioneers in brachytherapy research initially theorized about the use of Cesium-131 in a titanium capsule, however scientific and economic limitations at the time prevented its development and Iodine-125 emerged as an alternative.
Beginning in 1967, Iodine-125 became the first radioisotope manufactured in a titanium capsule, or seed. While its use continues to this day, many patients and doctors in recent years have chosen Palladium-103, a faster-acting, shorter half-life isotope than Iodine-125. In order to obtain the clinical benefits of Palladium’s short half-life, patients and clinicians were forced to settle for lower energy or tissue penetrating power.
A team of scientists continued to believe the physical characteristics of Cesium-131* could potentially provide superior clinical benefits for seed brachytherapy patients. The team developed the patented process for economically separating and purifying Cesium-131 and in 1998 Isoray was founded to manufacture and commercialize Cesium-131 brachytherapy seeds to treat cancers.
Join Us at the Following Events
American Association of Neurological Surgeons
April 22 – 26, 2017
Los Angeles, CA
American Urologic Association Annual Meeting 2017
May 12- 16, 2017
Why we are looking forward to SGO 2017: Breakthroughs in treating gynecologic cancer including Cesium-131 Permanent Interstitial Brachytherapy (PIB)
Isoray is excited to be supporting the upcoming Society of Gynecologic Oncology (SGO) annual meeting, which will be held March 12-15 in National Harbor, Maryland. The SGO meeting serves as a forum on women’s cancer, providing the latest clinical updates and research...
The Society of Thoracic Surgeons Annual Meeting is the pinnacle of scientific education and new research results delivery in the global cardiothoracic community. Included within this community are the surgeons treating lung cancer patients. Through this lens, Isoray...
What 2017 has in store for Isoray as we seek to better patient outcomes and broaden our network of champion physicians
The successes Isoray Medical celebrated, and the milestones attained in 2016, have set a strong foundation that will allow us to catapult forward into 2017. We expect to continue to build on these successes in 2017, as we leverage our new web presence to share the...
Developing Seed Brachytherapy and Medical Radioisotope Applications for the Treatment of Multiple Cancers
Earlier this month, Isoray Chairman of the Board and CEO Tom LaVoy spoke with SNNLive about our Cesium-131 brachytherapy solution for multiple types of cancer at the LD Micro "Main Event" 2016 in Bel Air, CA. Tom and SNN host Shelly Kraft discussed in detail the...
It has been an amazing year for the IsoRay team. The last 12 months have been marked by the release of groundbreaking data for our Cesium-131 Brachytherapy, the realignment of our management team, and a new web presence to maximize our reach and convey our messaging....
Topic of Two Presentations at the 2016 Annual Meeting of the American Brachytherapy Society and World Congress of Brachytherapy RICHLAND, Wash., July 6, 2016 /PRNewswire/ — IsoRay Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy...
95% of Targeted Cancers Showed No Regrowth of Tumor at the Operative Site RICHLAND, Wash., June 21, 2016 /PRNewswire/ — Isoray Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the...
IsoRay Appoints Michael L. Krachon as Vice President of Sales and Marketing and Lori A. Woods as Senior Marketing Consultant
Richland, WA – March 2, 2016 – IsoRay Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the...
Richland, WA January 14, 2016 – IsoRay Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the...